1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited

GLAXO.BO
GlaxoSmithKline Pharmaceuticals LimitedIN flagBombay Stock Exchange
2,400.60
INR
+7.85
- -
407.14BMarket Cap
GlaxoSmithKline Pharmaceuticals Limited
GLAXO.BO
(Bombay Stock Exchange)

Recent

price

2,400.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
126.98
142.27
156.45
150.81
- -
158.45
171.69
165.64
182.92
188.84
171.15
192.68
190.45
203.17
219.95
- -
220.78
Revenue per Share
33.09
25.3
33.17
28.43
- -
22.2
19.88
20.7
26.29
5.5
21.14
100.04
36.05
34.83
54.76
- -
56.1
Basic EPS, GAAP
27.03
17.31
18.51
16.61
- -
8.2
13.83
27.91
24.17
19.6
31.5
45.81
25.98
32.51
74.68
- -
- -
Free Cash Flow per Basic Share
14.94
19.93
22.32
24.87
- -
31.25
25
15
17.5
20
39.97
29.91
90.05
31.97
44.24
- -
- -
Dividend per Share
5
72.27
73.03
69.03
186.13
77.67
67.25
70.23
80.29
61.68
42.82
112.21
57.9
61.74
72.49
- -
- -
Book Value per Share
115.2
114.26
118.46
117.45
288.55
128.88
116.56
117.15
122.44
104.54
84.7
155.16
100.77
103.54
114.4
- -
- -
Tangible Book Value per Share
169
169
169
169
85
169
169
169
169
169
169
169
169
169
169
- -
169
Basic Weighted Avg Shares
21,511
24,102
26,504
25,548
- -
26,843
29,085
28,061
30,987
31,991
28,994
32,641
32,264
34,418
37,260
38,076
37,397
Sales/Revenue/Turnover
40.52
32.76
30.07
20.33
- -
17.21
13.5
16.98
17.96
18.36
17.92
21.41
23.2
24.36
29.91
32.77
30.27
Operating Margin (%)
176
204
178
199
- -
249
263
380
486
827
786
682
658
697
668
664
659
Depreciation Expense
5,606
4,286
5,619
4,817
- -
3,761
3,368
3,507
4,454
932
3,581
16,947
6,107
5,900
9,276
10,360
9,503
Net Income, GAAP
33.66
29.13
32.66
32.3
- -
34.97
34.11
35.05
34.76
69.52
36.72
51.12
27.35
27.72
26.38
26.32
26.31
Effective Tax Rate (%)
26.06
17.78
21.2
18.85
- -
14.01
11.58
12.5
14.37
2.91
12.35
51.92
18.93
17.14
24.89
27.21
25.41
Profit Margin (%)
16,646
17,455
18,103
17,350
20,742
15,888
9,524
5,816
5,551
7,506
8,481
20,096
11,679
12,735
15,047
18,280
- -
Working Capital
52
46
41
36
26
16
10
6
2
269
202
76
35
65
25
173
- -
LT Debt
19,516
19,357
20,068
19,897
24,441
21,832
20,069
20,573
21,398
18,206
14,783
26,630
17,413
17,776
19,513
22,674
- -
Total Equity
30.86
28.78
27.3
17.65
- -
12.97
12.4
14.77
16.23
8.36
17.95
14.8
21.75
29.41
36.05
34.7
- -
Return on Invested Capital (%)
622.86
65.01
45.5
39.9
- -
25.98
27.41
30.09
34.94
7.76
39.03
126.49
41.96
57.38
80.66
73.52
441.1
Return on Capital (%)
661.81
65.48
45.65
40.03
- -
26.01
27.44
30.12
34.93
7.75
40.46
129.06
42.38
58.22
81.59
74.52
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
75
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
25
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
169
- -
Market Capitalization
381,492
487,400
573,671

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
34,099
- -
Cash, Cash Equivalents & STI
- -
24,981
- -
Accounts Receivable, Net
- -
2,925
- -
Inventories
- -
4,817
- -
Total Current Liabilities
- -
19,052
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
75
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.83%
14.72%
16.2%
Free Cash Flow
32.29%
24.8%
-32.97%
Net Income, GAAP
60.06%
74.95%
11.69%
Sales/Revenue/Turnover
3.77%
5.71%
2.19%
Total Cash Common Dividend
21.59%
29.02%
-4.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,617
9,570
8,053
9,179
34,418
2025
8,146
10,108
9,494
9,744
37,260
2026
8,052
10,413
9,953
- -
38,076

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7.81
12.84
2.7
- -
34.83
2025
10.76
14.91
13.57
15.52
54.76
2026
12.1
17.45
16.4
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
31.97
2025
- -
- -
- -
- -
44.24
2026
- -
- -
- -
- -
- -
Similar Companies
Daiichi Sankyo Company, Limited (DSKYF)
Daiichi Sankyo Company, Limited (DSNKY)
Novo Nordisk A/S (NVO)
Bristol-Myers Squibb Company (BRM.DE)
Marksans Pharma Limited (MARKSANS.NS)
JCR Pharmaceuticals Co., Ltd. (JCRRF)
Business
GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc, focusing on the manufacture, marketing, and distribution of pharmaceutical products in India. The company provides a broad portfolio including prescription pharmaceuticals, vaccines, consumer healthcare products, veterinary medicines, and laboratory chemicals. Key product categories encompass specialty medicines for respiratory diseases, oncology, immunology and inflammation, HIV, and infectious diseases; vaccines targeting a range of infectious diseases across life stages; and general medicines such as inhalers for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and dermatological treatments. Notable brands include Phexin capsules, Betnesol tablets and injections, Becoride for asthma, Betnovate ointments, Cetzine antihistamine, and anti-tuberculosis products Zucox and Rizap. Recent strategic developments include the company's entry into oncology with the launch of precision therapies Jemperli and Zejula, specifically addressing gynecological cancers. GSK has also completed the acquisition of efimosfermin alfa, a promising specialty medicine in late-stage development for steatotic liver disease, and expanded its research pipeline through agreements with Hengrui Pharma to co-develop multiple novel candidates. These moves reflect a strategic emphasis on specialty medicines and innovation in targeted therapies. The company continues to leverage global scientific expertise and maintains a strong presence in the Indian pharmaceutical market while aligning with GSK plc’s broader focus on immunology, oncology, respiratory diseases, and vaccines. Founded in 1924 and headquartered in Mumbai, India, GlaxoSmithKline Pharmaceuticals Limited serves diverse customer segments including hospitals, clinics, and pharmacies across India and select global regions. The company operates as part of GSK plc's global biopharma network, benefiting from integrated research, technology platforms, and global scale in commercial operations. Its product portfolio and recent acquisitions underscore commitment to addressing unmet medical needs through both established pharmaceutical products and innovative new therapies. This comprehensive approach to specialty pharmaceuticals, vaccines, and consumer health products positions GlaxoSmithKline Pharmaceuticals Limited as a significant player in the Indian healthcare industry with strategic growth initiatives centered on oncology and advanced specialty medicines within the last two years.